Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Search
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
Stroke Risk Factors Symptoms
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. There is a simple test that can help everyone identify the most common symptoms of a stroke.
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Imagine: The impact of volunteering activities on elderly well-being
How our employees contribute to elderly well-being with creative volunteering activities in Australia, South Korea, Southeast Asia, and New Zealand.
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
Boehringer Ingelheim invests in precision cancer treatments
Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
Living with GPP
Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
bix_facilitates_global_partnerships
BI X focuses on partnerships to speed up the development of digital healthcare solutions
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.